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Background: There is no consensus on the optimal treatment for
patients with advanced non-small cell lung cancer and stable disease
after cisplatin-based chemotherapy. The objective of the trial was to
evaluate a switch to a different dual-agent chemotherapy.
Methods: Patients with stage IV non-small cell lung cancer and
stable disease after two cycles of cisplatin (P) and gemcitabine (G)
(P day1 (d1): 75 mg/m
2, G: 1250 mg/m2 d1 and d8 every 3 weeks)
were randomized to receive either two further cycles of PG (arm A)
or paclitaxel (100 mg/m2 d1, d8, d15) plus gemcitabine (1250 mg/m
2
d1 and d8, every 4 weeks) (arm B).
Results: Two-hundred-twenty-eight patients were enrolled between
October 2003 and August 2006. After two cycles of PG, 98 patients
(43%) had stable disease; 87 were randomized: 45 to arm A and 42
to arm B. The objective response rates were 15.6% (6.5–29.4) and
21.4% (10.3–36.8) in arms A and B. Overall survival after random-
ization was 9.6 months (7.0–13.8) in arm A and 9.3 months
(7.4–13.3) in arm B. Adverse events were similar in the two arms
for hematological and non hematological toxicities.
Conclusions: Sequential first-line chemotherapy in these patients is
feasible with no difference in response rates. These results do not
warrant a phase III trial.
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The first-line treatment generally recommended for patientswith stage IV non-small cell lung cancer (NSCLC) who
are in good general condition (performance status 0 or 1)
consists of four to six cycles of doublet chemotherapy with a
platinum salt plus a third-generation drug. The drugs usually
combined with platinum are docetaxel, paclitaxel, vinorel-
bine, and gemcitabine, all of which have similar efficacy.1–3
Most responses occur early after two cycles of chemotherapy.4
Responder patients show a symptomatic improvement in 61%
of cases after 1 course of chemotherapy and in 96% of cases
after 2 courses.5 Given the cumulative toxicity of platinum
salts, these data support early assessment of the treatment re-
sponse, after only two courses. The choice of treatment is then
fairly simple for responders (the same treatment should be
continued) and also for patients who progress (second-line
treatment, depending on their general condition). More prob-
lematic in clinical practice is the case of patients with stable
disease after two courses of cisplatin-based therapy. Indeed,
stabilization depends on the growth kinetics of the tumor, its
cellular heterogeneity, and treatment efficacy. The RECIST
criteria6 define patients with stable disease as those with
responses below 30% and progression below 20%. However,
these patients are heterogeneous, some having an early re-
sponse and others progressing. In addition, tumor stabiliza-
tion on treatment can provide a survival benefit.7 This is
clearly the case of second-line treatments, where the rate of
disease control and the time to progression both correlate
with survival.8,9 Evaluation of the clinical benefit possibly
associated with tumor stabilization can contribute to the
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choice of subsequent therapy. In clinical practice, disease stabi-
lization during chemotherapy, especially after early assessment,
raises the choice between continuing with the same drugs and
switching to a different chemotherapy regimen. Switching treat-
ment allows other active drugs to be introduced, while at the
same time avoiding cross-resistance10,11 and cumulative toxicity.
Alternative chemotherapies have already been used,12,13 but no
survival benefit has so far been demonstrated. The use of a
platinum-free doublet could reduce toxicity14 while preserving
efficacy.15 Alternating paclitaxel and gemcitabine administration
has been proposed as first-line treatment,16 based on synergistic
effects.17 The present study (the Groupe Franc¸ais de Pneumo-
Cance´rologie GFPC 03-01 trial) was designed to evaluate the
consequences of replacing a platinum salt by paclitaxel in
patients with stable NSCLC after two courses of cisplatin-
gemcitabine combination therapy. We postulated that the se-
quential treatment might yield better response rates, longer
survival, and less toxicity. The choice of the weekly regimen
was based on previous studies,16,18 which showed that weekly
infusions yielded better dose intensity with less toxicity.
PATIENTS AND METHODS
Patients
Patients were eligible if they had never-treated, histolog-
ically or cytologically proven stage IV or pleural stage IIIB
NSCLC (adenocarcinoma, squamous cell carcinoma, large-cell
carcinoma), a performance status 2, age between 18 and 70
years, a measurable target lesion according to the RECIST
criteria,6 satisfactory renal, hematologic and cardiac function, no
peripheral neuropathy and no other chronic progressive disease.
The patients’ written informed consent was required. Patients
were ineligible if they had other histologic types, brain metas-
tases, a superior vena cava syndrome, any severe organic disor-
der, a history of cancer, or concurrent radiotherapy. Exclusion
criteria included contraindications to steroid therapy and allergy
to Polysorbate 80. The initial evaluation comprised a physical
examination, hematological, hepatic and renal tests, tumor as-
sessment based on radiography, cerebral, thoracic and subdia-
phragmatic computed tomography, bone scintigraphy, and a
cardiac and neurologic work-up. The protocol was approved by
the ethics committee of Limoges Hospital on July 29, 2003.
Treatment Protocol
We chose a phase II randomized trial format because it
allowed us to assess the effectiveness of the experimental arm
with a small number of patients, before possibly proceeding with
a phase III trial (which needed more patients). The inclusion of
a standard treatment arm helped to avoid a selection bias served
to control the response rate with the usual treatment. Random-
ization was stratified according to performance status (0 versus
1), and the number of metastatic sites (1 versus 1). The
patients received two 21-day courses of cisplatin-gemcitabine
(cisplatin 75 mg/m2 day 1 (d1), gemcitabine 1250 mg/m
2, d1, d8)
with dose adjustment according to hematological status. If the
nadir polymorphonuclear cell count was below 500 for 7 days
and/or the platelet count was below 25,000, the gemcitabine and
cisplatin doses were reduced by 20%. The patient left the trial if
a new episode occurred after this first dose reduction. If the
blood cell counts before each course showed a polymorphonu-
clear neutrophil count below 1500 and/or a platelet count below
100,000, treatment was postponed for a week. If treatment had
to be postponed for more than 2 weeks, the patient left the trial.
The doses were also adjusted in case of peripheral neurotoxicity
and renal or hepatic impairment. After these two treatment
courses, patients who were not assessable, patients who were in
progression and patients who had objective responses left the
study and were treated as decided by the investigator. Patients
with stable disease in the RECIST system were randomized
between two new 21-day courses of cisplatin-gemcitabine (arm
A, control) or two 21-day courses of paclitaxel-gemcitabine, as
described by De Pas,18 consisting of paclitaxel 100 mg/m2 on d1,
d8, and d15; and gemcitabine 1250 mg/m
2 on d1 and d8 (arm B,
experimental). In case of hematological toxicity (polymorpho-
nuclear neutrophils 1500 and/or platelets 100,000), treat-
ment with paclitaxel and gemcitabine was postponed for a week
and the doses of the two drugs were reduced by 20%. If
treatment had to be postponed more than twice for a week, the
patient left the trial. Regardless of the treatment arm, after
completing the four courses the patients were simply monitored
until they progressed. The choice of treatment after disease
progression was left to the investigator.
Endpoints
The response to treatment was evaluated every two
courses (with the repetition of the initial examination to
evaluate the target was done systematically). Supplementary
investigations were performed if clinical signs of disease
progression were present. Responses were defined according
to RECIST criteria.6 Toxicity was assessed with National
Cancer Institute-Common Toxicity Criteria (version 2.0).19
Treatment was halted in case of toxicity, progression, study
completion, or refusal to continue. All objective responses
were confirmed 4 weeks later. All evaluations were reviewed
blindly by the GFPC panel of investigators. Grade III
toxicity was also reviewed by the panel, together with the
potential responsibility of the study treatments.
Statistical Analysis
The main end point was rate of objective responses after
four courses (two courses after randomization) in the intention-
to-treat analysis. The required number of patients for the exper-
imental arm was calculated with Simon’s two-step method.20
For a type 1 error of 5%, a type 2 error of 20%, the required
number of subjects was 18 for stage 1 and 43 for stage 2, with
the above hypotheses: the experimental strategy had to be
rejected at the first stage if the response rate was 10% (2
responses or less/18); passage to phase III would be recom-
mended if the response rate was 25% (8 responses or more/
43), with sufficient efficacy. A secondary end point was the
response duration in patients with objective responses. Progres-
sion free survival (PFS) and overall survival (OS) were studied
in all the patients (from an intent to treat perspective). Tolera-
bility was analyzed per course and per patient in all the patients.
Quantitative variables were expressed as means or medians and
standard deviations or interquartiles ranges. Qualitative variables
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were expressed as frequency and percentages with 95% confi-
dence intervals. Percentages were compared between groups by
using the 2 test or Fisher’s exact test as appropriate. Quantita-
tive variables were compared with Student t test or Wilcoxon’s
test for unpaired series when the variable was not normally
distributed. OS, PFS, and time under observation were analyzed
with the Kaplan-Meier method. Given the objective of the study,
the two treatment arms were not compared with each other. SAS
software version 8 (SAS Inc., Cary, NC) and Epi-Info V6.04
(CDC, Atlanta) were used for statistical analysis.
RESULTS
Between October 2003 and August 2006, 228 patients
were enrolled in the study by 30 centers (Appendix). Their
characteristics are shown in Table 1. Most of the patients
FIGURE 1. Flow chart of the study.
TABLE 1. Characteristics of the Overall Population and of the Two Treatment Subgroups (n  87)
All Patients
(n  228)
Arm A
(n  45)
Arm B
(n  42)
N % N % N %
Agea (yr) p  0.004b
Median 57 59 56
Range (52–62) (55.9–60.3) (52.6–57.2)
Sexc p  0.54b
Male 182 79.8 34 75.6 34 81
Female 46 20.2 11 24.4 8 19
Performance statusc p  0.76b
0 110 48.2 21 46.7 21 50
1 118 51.8 24 53.3 21 50
Histological typec p  0.48
Squamous cell 54 23.7 28 62.2 26 62
Adenocarcinoma 139 61.3 12 26.7 8 19
Large cell 35 15.3 5 11.1 8 19
Metastatic sitesc p  0.54b
1 89 39.0 20 44.4 16 38
1 139 61.0 25 55.6 26 62
Stagec p  0.53b
IIIB 7 3.1 2 4.4 1 2.4
IV 221 96.9 43 95.6 41 97.6
a Student t test.
b Comparison between arm A and B.
c 2 or Fisher’s exact test.
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were men (80%) and 61% had adenocarcinomas. After 2
courses of cisplatin-gemcitabine, 59 patients 25.9%; 20.3–
32.1 were in progression, 44 19.3%; 14.4–25.0 had objec-
tive responses, and 27 11.8%; 7.9–16.8 were not assessable.
The investigators considered that 98 patients 43%; 36.9–
49.7 had stable disease, but panel review subsequently ex-
cluded 4 patients (1 in progression and 3 with objective
responses). Furthermore, one patient refused to continue the
protocol and six had a deterioration of their performance
status that prevented them from continuing in the study
(Figure 1). Thus, 87 patients were randomized, 45 to arm A
and 42 to arm B. As shown in Table 1, the characteristics of
the patients were similar in the two arms, although mean age
was slightly higher in arm A. The first stage, focusing on 18
patients, showed 3 objective responses in arm B (paclitaxel-
gemcitabine), with acceptable toxicity, authorizing the study to
continue. Six patients were not assessable in the final analysis
(three in each arm). At the end of the two stages, among the
randomized patients, the objective response rate was 15.6%
6.5–29.4 (7 patients) in arm A (continued cisplatin 
gemcitabine) and 21.4% 10.3–36.8 (9 patients) in arm B
(paclitaxel–gemcitabine). The rate of disease control was
68.9% in arm A and 80.9% in arm B. Numerically, there were
more progressions in arm A and more cases of stable disease
and responses in arm B (Table 2, Figure 2). Among the non
randomized patients, the relative dose intensity was 0.98 for
cisplatin and 0.97 for gemcitabine after 2 courses. For pa-
tients randomized to arm B, after 4 courses the relative dose
intensity was 0.99 for cisplatin, 0.99 for paclitaxel, and 0.97
for gemcitabine. For patients randomized to arm A, it was
0.98 for cisplatin and 0.96 for gemcitabine. Progression-free
survival and OS, calculated from the randomization date,
were similar in the two arms, (Figure 3). The median PFS,
also calculated from randomization was 7.4 months 5.4–
11.4 in arm A and 6.9 months 5.0–9.0 in arm B. The
median survival time from the date of diagnosis was 11.0
months 8.6–15.4 in arm A and 10.7 months 8.7–14.9 in
arm B. Among the non randomized patients, the median
survival time after inclusion was 13.8 months for responders
and 4.7 months for patients who were in progression after two
courses. The dynamics of the responses differed in the two
arms. In arm A (control), the response rate was the same after
four courses as after two courses. In arm B (experimental),
some new responses were obtained after the full four courses
compared with the first two courses (Figure 2). Toxicity was
acceptable in both arms (Table 3). No grade 3–4 nausea-
vomiting or grade III/IV neurologic toxicity occurred in arm B.
DISCUSSION
This is the first randomized phase II trial of early
modification of a chemotherapy cisplatin doublet with pacli-
taxel in patients who had stable NSCLC after two courses of
a platinum-based two-drug regimen. Such patients are highly
heterogeneous, some having a reduction in the target tumor
and others an increase, but the change is not sufficient to
comply with the definition of an objective response or disease
progression. Our results showed that sequential chemother-
apy is feasible, with no major toxicity. Despite different
response rates, however, the OS and TTP were similar in the
two arms. Nevertheless, considering our working hypotheses,
the response rate obtained in the experimental arm does not
warrant a phase III trial of this sequential strategy. Sequential
chemotherapy is a controversial topic. It can be based on two
or one drugs, as in recent studies,21,22 but in these two trials
the switch was performed later, after four and six cycles.
Only progression-free survival was improved. We chose to
test an early switch Novello et al.23 have reported that five
courses of a cisplatin-gemcitabine doublet is superior to two
courses with both drugs followed by three courses of gem-
citabine monotherapy. Finally, it seemed better to switch
FIGURE 2. Part A, Percentage change in tumor volume be-
tween evaluation two (four courses) and evaluation one (two
courses) in arm A (45 patients). Part B, Percentage change in
tumor volume between evaluation two (four courses) and
evaluation one (two courses) in arm B (42 patients).
TABLE 2. Tumor Responses After Randomization (n  87)
Arm A
n  45
Arm B
n  42
N % 95% CI N % 95% CI
NA 3 6.7 (1.4–18.3) 3 7.2 (1.5–19.5)
PD 11 24.4 (12.9–39.5) 5 11.9 (4.0–25.6)
SD 24 53.3 (37.9–68.3) 25 59.5 (43.3–74.4)
OR 7 15.6 (6.5–29.5) 9 21.4 (10.3–36.8)
NA, not assessable; PD, progressive disease; SD. stable disease; OR, objective
response; CI, confidence interval.
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early after the chemotherapeutic sequence rather than in case
of progression.24 Our study examined this unresolved ques-
tion on the use of sequential treatments. Some studies are
very similar to ours, but most involved relatively small and
heterogeneous populations, ruling out meaningful compari-
sons. Some studies involved an early switch in chemotherapy
for all the patients, regardless of the response after the first
two courses,25–27 while others involved only patients whose
disease was controlled after the first two courses.13,28 In
addition, it is not always easy to compare response rates
between the different treatments, because some authors only
calculated the overall response rate for the two phases.
However, our results are compatible with all previous reports.
Thus, in the study by Dongiovanni et al.,27 involving 55
patients receiving 2 courses of cisplatin plus vinorelbine
followed by 2 courses of paclitaxel plus gemcitabine, the
objective response rate was 27% after the first 2 courses but
42% after 4 courses. Another study12 showed that alternative
drug administration (docetaxel or vinorelbine) in associated
with cisplatin did not improve the objective response rate.
Finally, in a phase III trial,13 patients were randomized, after
FIGURE 3. Part A, Progression-free
survival (PFS) in months (m) among
randomized patients (n  87) accord-
ing to the Kaplan Meier method. Part
B, Overall survival (OS) in months (m)
among randomized patients (n  87)
according to the Kaplan Meier
method.
TABLE 3. Grade III–IV Toxicities and Percentages,
According to the Cycle Number
After Two
Cycles
n  432
Arm A
n  84
Arm B
n  82
N % N % N %
Hematological toxicity
Neutropenia 64 14.8 14 16.7 8 9.8
Febrile neutropenia 3 0.7 1 1.2 3 3.7
Thrombocytopenia 27 6.2 6 7.1 3 3.7
Anemia 18 4.2 4 4.8 4 4.9
Leucopenia 3 0.7 1 1.2 1 1.2
Non hematological toxicity
Renal toxicity 7 1.6 — —
Fatigue 11 2.5 3 3.6 3 3.6
Nausea vomiting 12 2.8 2 2.4 —
Unexpected eventa 21 4.9 2 2.4 3 3.6
a Thrombophlebitis, ischemia, alopecia, pulmonary infection, allergy, diarrhea,
fever.
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three courses of cisplatin-ifosfamide-gemcitabine, either to
three supplementary courses of cisplatin-ifosfamide-gemcit-
abine or to paclitaxel. As in our study, this phase III trial
showed that a three drug combination followed after three
cycles by paclitaxel does not result in better outcome com-
pared with cisplatin based chemotherapy. The type of re-
sponse (objective or non change) was not a significant prog-
nosis factor. Our study has certain limitations. The response
evaluation at 7 weeks, after only two courses of cisplatin-
based therapy, may be considered premature. However, al-
most all the responses in the control arm were obtained after
the first two courses, the following two courses increasing the
response rate by only 15%. Likewise, the choice of 3-week
cycles (meaning that the response had to be evaluated after 7
weeks) may be open to criticism, but early response assess-
ment is now a validated option. The choice of a phase II
randomized trial design ruled out certain comparisons but
confirmed that there was no loss of chance in the sequential
arm with respect to OS or the time to progression. In addition,
only 15% more responses were obtained in the cisplatin-
gemcitabine arm. One another limit is the study design: the
protocol was drawn up in late 2002, before the widespread
use of pharmacogenomics in lung cancer patient manage-
ment.29 Individual treatment tailoring based on criteria pre-
dictive of efficacy or tolerability will help to optimize therapy
for patients with stable disease.
CONCLUSION
The GFPC 03-01 trial shows that sequential chemother-
apy is feasible in patients who have stable NSCLC after two
courses of cisplatin, without major toxicity. This phase II
randomized study shows no evidence that switching regimen
may results in higher response rates. The response rate in the
experimental arm is too low to warrant a phase III study witch
the same sequential strategy.
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